Can engineered immune cells tackle a tough kidney disease?

NCT ID NCT07765537

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recognize and attack certain targets (BCMA and CD19) that may be driving the disease. The study aims to see if this approach is safe and whether it can reduce protein in the urine, a key sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FKC289, a type of CAR-T cell therapy using the patient's own immune cells engineered to target BCMA and CD19
What this could lead to: If successful, this could offer a new treatment option for people with membranous nephropathy that has not responded to standard therapies, potentially reducing protein in the urine and preserving kidney function.
What could go wrong: This is an early-stage trial (Phase I/II) with a small number of participants. CAR-T therapies can cause serious side effects, and it is unknown if this approach will be safe and effective for kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Nanjing General Hospital of Nanjing Military Command

Nanjing, Jiangsu, 210000, China
Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China
Shenzhen People's Hospital

Shenzhen, Guangdong, 518020, China
Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610072, China
The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510080, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China
Xiangya Hospital of Central South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.